Science & Medical |
Emyria Limited

Emyria partners with Mind Medicine Australia to develop national care program and data registry for psychedelic-assisted therapies

Highlights:

  • ●  Emyria and Mind Medicine Australia to develop an evidenced based, best practice, model to support the safe and appropriate initiation, delivery and monitoring of psychedelic-assisted therapies in Australia

  • ●  Partnership will also develop a national clinical evidence registry to support research into the

    safety, effectiveness and cost benefits of psychedelic-assisted therapy enabled by Emyria’s Real-World Evidence (RWE) data platform

  • ●  Initial focus will be specialist-directed use of MDMA assisted therapies for treatment resistant post-traumatic stress disorder and psilocybin assisted therapies for treatment resistant depression

  • ●  Partnership to leverage Emyria’s experience with unregistered medicines for patients with unmet needs across its national network of clinics – Emerald Clinics

    Emyria Limited (ASX: EMD) (Emyria or the Company), a company that accelerates treatment development for patients with unmet needs, is pleased to announce a partnership with Mind Medicine Australia to co- develop a gold-standard and data-driven clinical model for the safe provision of psychedelic-assisted therapies in Australia.

    Emyria’s Managing Director, Dr Michael Winlo, said: “We’re delighted to support Mind Medicine Australia by developing a scalable psychedelic-assisted therapy care model for patients suffering from treatment resistant post-traumatic stress disorder, treatment resistant depression and substance abuse. Emyria has unique expertise caring for patients with unmet needs while also generating high quality clinical evidence using our RWE data platform. This partnership has the potential to expand the therapeutic options available for our patients with unmet needs while also creating a unique data registry that can accelerate treatment development and registration.”

    Emyria will also apply its remote monitoring technology and lead the construction of a longitudinal data registry. The registry will collect real world clinical data on diagnoses, concomitant medications, dosing information and patient responses to psychedelic-assisted treatments as measured using validated clinical and patient-reported endpoints. The data will support ongoing research into the safety, effectiveness and cost benefits of psychedelic-assisted therapies for major mental health concerns compared to current alternatives.

    Mind Medicine Australia’s Chairman, Peter Hunt AM, said, “Mental health is a growing global health concern and new care models are needed. Psychedelic-assisted therapies show incredible promise, but further high- quality clinical evidence is needed to demonstrate their effectiveness. This is why we’re excited to work with Emyria, who can help us develop a model of care that provides patients safe access to these promising treatments. The partnership will also allow us to generate high-quality data, which can inform ongoing research and development efforts and guide evidence-based access to these therapies for patients in need, where appropriate.


    - ENDS - 

    For further information please contact: 

    Lexi O’Halloran

    Media/Investor Relations
    + 61 (0) 404 577076

     lexi@janemorganmanagement.com.au


Media

Photos

941106